Homology modeling and SAR analysis of Schistosoma japonicum cathepsin D (SjCD) with statin inhibitors identify a unique active site steric barrier with potential for the design of specific inhibitors
暂无分享,去创建一个
Pavel Majer | Jirí Vondrásek | J. Konvalinka | M. Sajid | J. Vondrášek | J. McKerrow | C. Caffrey | C. Bařinka | J. Dostál | Mohammed Sajid | James H McKerrow | Jan Konvalinka | Conor R Caffrey | P. Majer | Cyril Barinka | Martin Hradilek | Lenka Placha | Jirí Dostál | M. Hradílek | L. Plachá
[1] Feng Liu,et al. Evolutionary and biomedical implications of a Schistosoma japonicum complementary DNA resource , 2003, Nature Genetics.
[2] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[3] D. Veber,et al. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. , 1988, Biochemical and biophysical research communications.
[4] C. Morris,et al. Identification and characterisation of an aspartyl protease inhibitor homologue as a major allergen of Trichostrongylus colubriformis. , 2003, International journal for parasitology.
[5] M Hendlich,et al. Databases for protein-ligand complexes. , 1998, Acta crystallographica. Section D, Biological crystallography.
[6] K. Fujikawa,et al. Aspartic protease inhibitors from the parasitic nematode Ascaris. , 1991, Advances in Experimental Medicine and Biology.
[7] R E Cachau,et al. Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Collins,et al. Structure‐based subsite specificity mapping of human cathepsin D using statine‐based inhibitors , 1997, Protein science : a publication of the Protein Society.
[9] I. Pichová,et al. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. , 2001, European journal of biochemistry.
[10] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[11] C. Abad-Zapatero,et al. Candida proteases and their inhibition: prospects for antifungal therapy. , 2001, Current medicinal chemistry.
[12] Edward J. Pearce,et al. The immunobiology of schistosomiasis , 2002, Nature Reviews Immunology.
[13] M. Sajid,et al. Blood 'n' guts: an update on schistosome digestive peptidases. , 2004, Trends in parasitology.
[14] Robert D Clark,et al. Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors. , 1996, Journal of medicinal chemistry.
[15] L. Schmidt,et al. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto‐oncogene: Modeling studies , 2001, Proteins.
[16] B. Anderson,et al. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. , 1995, Structure.
[17] L. Chitsulo,et al. Focus: Schistosomiasis , 2004, Nature Reviews Microbiology.
[18] J. Dalton,et al. Cloning and Characterization of the Schistosoma japonicum Aspartic Proteinase Involved in Hemoglobin Degradation (*) , 1995, The Journal of Biological Chemistry.
[19] C. Caffrey,et al. Schistosoma japonicum and S. mansoni: effect of cyclosporin A on aspartic and cysteine hemoglobinolytic activities , 1998 .
[20] V. Tomášek,et al. Isolation and some properties of cathepsin D inhibitor from potatoes , 1976 .
[21] A. Loukas,et al. Hookworm aspartic protease, Na-APR-2, cleaves human hemoglobin and serum proteins in a host-specific fashion. , 2003, The Journal of infectious diseases.
[22] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[23] D. Nisato,et al. Stereospecific synthesis of N-protected statine and its analogues via chiral tetramic acid , 1987 .
[24] T. Halgren,et al. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. , 1995, Journal of medicinal chemistry.
[25] D. Fairlie,et al. Proteolysis of human hemoglobin by schistosome cathepsin D. , 2001, Molecular and biochemical parasitology.
[26] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[27] J. McKerrow,et al. Cysteine protease inhibitors block schistosome hemoglobin degradation in vitro and decrease worm burden and egg production in vivo. , 1996, Molecular and biochemical parasitology.
[28] S. Giovanni-De-Simone,et al. Exploring the subsite specificity of Schistosoma mansoni aspartyl hemoglobinase through comparative molecular modelling , 2002, FEBS letters.
[29] A. Ruppel,et al. Schistosoma mansoni and S. japonicum: comparison of levels of ultraviolet irradiation for vaccination of mice with cercariae , 1990, Parasitology.
[30] A. Loukas,et al. Hemoglobin-degrading, Aspartic Proteases of Blood-feeding Parasites , 2001, The Journal of Biological Chemistry.
[31] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[32] V. Kulkarni,et al. Insights into the selective inhibition of Candida albicans secreted aspartyl protease: a docking analysis study. , 2002, Bioorganic & medicinal chemistry.
[33] A Wlodawer,et al. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.